Cite
HARVARD Citation
Patil, V. et al. (2022). Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. Oral oncology. p. . [Online].